Literature DB >> 6225118

Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

M K Pangburn, R D Schreiber, H J Müller-Eberhard.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia in which the erythrocytes are abnormally sensitive to lysis by complement. A functional deficiency of membrane-associated complement regulators has been demonstrated on PNH erythrocytes. The two factor H-like proteins, the C3b receptor (CR1) and the decay-accelerating factor (DAF), were isolated from normal human erythrocytes, and specific antisera were prepared. Selective inhibition of the two proteins on normal erythrocytes by the antisera demonstrated (i) that the factor responsible for accelerated decay of erythrocyte-bound C3 convertase is DAF and (ii) that the cofactor required for inactivation of erythrocyte-bound C3b by factor I is CR1. PNH erythrocytes were deficient in both of these activities. Erythrocytes deficient in CR1, which were obtained from an apparently healthy individual, exhibited normal DAF activity but no factor I cofactor activity. These cells were not susceptible to complement-mediated lysis in acidified human serum, whereas PNH erythrocytes and Pronase-treated human erythrocytes (which lack DAF and CR1 activities) were lysed by this treatment. It is suggested that the protein primarily responsible for preventing complement activation on normal human erythrocytes is DAF. AMr 73,000 protein isolated from the normal erythrocyte membranes of one PNH patient by using anti-DAF IgG was largely absent from the abnormal erythrocytes of this individual, suggesting that PNH cells lack the DAF protein. CR1 antigen, however, was present on the abnormal PNH erythrocytes. The results suggest that the primary molecular defect underlying the clinical manifestations of PNH may be the lack of the membrane-associated DAF protein and that the abnormal cells may also exhibit impaired CR1 function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225118      PMCID: PMC384270          DOI: 10.1073/pnas.80.17.5430

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies.

Authors:  N J Dobson; J D Lambris; G D Ross
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

2.  Selective inhibition of functional sites of cell-bound C3b by hybridoma-derived antibodies.

Authors:  J D Tamerius; M K Pangburn; H J Müller-Eberhard
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

3.  Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  C J Parker; P J Baker; W F Rosse
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

4.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.

Authors:  O Götze; H J Müller-Eberhard
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

5.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

6.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.

Authors:  D T Fearon
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

7.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

8.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

9.  Lysis of erythrocytes by complement in the absence of antibody.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307

10.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  95 in total

1.  Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.

Authors:  M K Pangburn
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

Review 2.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 5.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 6.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 7.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

8.  Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.

Authors:  H A Stafford; M L Tykocinski; D M Lublin; V M Holers; W F Rosse; J P Atkinson; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Authors:  Erin C Conrad; Yueh-Ya Hsu; David M Bortz; John G Younger
Journal:  J Innate Immun       Date:  2013-01-11       Impact factor: 7.349

10.  A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Authors:  J M Heckmann; H Uwimpuhwe; R Ballo; M Kaur; V B Bajic; S Prince
Journal:  Genes Immun       Date:  2009-08-13       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.